Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 6
Encontrada(s) 1 página(s)

Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Long-Term Impact of Peritoneal Dialysis Ultrafiltration on Cardiorenal Patients

  • Azancot Rivero, M Antonieta
  • León-Román, Juan
  • Núñez Delgado, Sara
  • Méndez Fernández, Ana Belén
  • Ramos Terrades, Natalia
  • TOAPANTA, NÉSTOR
  • Soler, María José
Cardiorenal syndrome; Diuretic resistance; Heart failure, Síndrome cardiorenal; Resistència diürètica; Insuficiència cardíaca, Síndrome cardiorrenal; Resistencia diurética; Insuficiencia cardíaca, Background: Heart failure (HF) prevalence is increasing, and its prognosis worsens in the presence of other comorbidities. Up to 70% of patients develop cardiorenal syndrome (CRS), which is associated with diuretic resistance or kidney deterioration over time. Peritoneal dialysis (PD) for ultrafiltration (PD-UF) could be a potential therapeutic option in CRS, although its long-term outcomes have not been described. Methods: Retrospective registry study of the Catalan Renal Registry on patients with PD-UF indication between 2013 and 2022. Baseline clinical characteristics and follow-up until December/2022 was studied. Results: Of the 1,874 incident patients on PD, 198 (10.6%) were PD-UF, 73.2% of the patients were male, and the mean age was 70.7 ± 9.3 years. Median estimated glomerular filtration rate (eGFR) at start was 22.6 (IQR: 14.8–32.8) mL/min×1.73 m2 and 75.0% have an eGFR above 15 mL/min×1.73 m2. Previous history of ischemic heart disease, arrhythmia, or cardiac surgery was recorded, and 57.6% of patients had ≥2 of these pathologies. The most common HF etiology was ischemic heart disease in 21.7% of patients. Median overall patient survival was 21 (IQR: 17.3–24.3) months. Technique survival at 1 year was 94.8%, and 27 patients were transferred to other renal replacement therapy (hemodialysis or kidney transplantation). In the Cox multivariate analysis, age ≥75 years (HR: 1.76 [95% CI: 1.20–2.59]), mild frailty (HR: 2.18 [95% CI: 1.17–2.59]), severe frailty (HR: 17.62 [95% CI: 1.20–55.48]), and the burden of cardiac disease (2 categories HR: 2.17 [95% CI: 1.05–4.47]; 3 categories HR: 2.26 [95% CI: 1.05–4.89]) were associated with poor overall survival. Technique survival was associated with eGFR (<30 mL/min×1.73 m2 HR: 5.64 [95% CI: 1.32–24.18]) and body mass index (<20 kg/m2 HR: 6.53 [95% CI: 1.06–40.12]) at baseline. Conclusion: PD-UF is a feasible option in patients with advanced HF and CRS. The complexity of this population increases with older age, frailty, and higher cardiac burden., M.J.S. received research funding from the Carlos III Health Institute (PI21/01292, PI24/01510). J.L.R. received a Rio Hortega grant from the Instituto de Salud Carlos III (CM23/00213). The authors are also recipients of other research grants from Instituto de Salud Carlos III (AC22/00029) and the Fundació la Marató de TV3 (202017-10, 202037-31, and 202133-30). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/0016 and RD24/0004/0031) and is recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Modelling CubAm function and regulation in proximal tubular cells using iPSC-derived kidney organoids

  • Bouwens, Daphne
  • van der Velde, max
  • Salvadó-Pau, Mireia
  • Vilardell-Vilà, Jordi
  • Lopez Hellin, Joan
  • Llorens Cebrià, Carmen
  • Duran, Monica
  • Martínez Díaz, Irene
  • Meseguer, Anna
  • Ferrer Costa, Roser
  • Soler, María José
  • Cantero-Recasens, Gerard
  • Jacobs-Cacha, Conxita
Amnionless; Apolipoprotein A-I; Cubilin, Sense amnion; Apolipoproteïna A-I; Cubilina, Sin amnion; Apolipoproteína A-I; Cubilina, Idiopathic nephrotic syndrome (INS) associated to focal segmental glomeruloesclerosis or minimal change disease is characterized by the presence of heavy levels of proteinuria. Filtrated proteins are normally actively reabsorbed in the proximal tubule by the megalin-cubilin-amnionless complex, located at the apical membrane of the proximal tubule epithelial cells. Megalin has a transmembrane domain but cubilin needs to interact with amnionless to reach the cell membrane in a complex known as CubAm. While megalin has a wide variety of ligands only a few proteins are exclusively transported by binding CubAm; one of those is Apolipoprotein A-I (ApoA-I). The reabsorption of Apolipoprotein A-I (ApoA-I) seems to be impaired in INS but this aspect of INS is difficult to study due to the low expression of CubAm in cultured proximal tubular cells as well as in other in vitro tubular modelling approaches. Here we show that RPTEC/TERT-1 cells cultured in monolayer barely express cubilin and amnionless proteins. In contrast, proximal tubular cells of induced Pluripotent Stem Cells (iPSCs)-derived kidney organoids showed robust expression of CubAm. In addition, protein overload induced an increase of the number of proximal tubular cells expressing cubilin that is reversed when the stimuli is removed. Finally, exogenously added ApoA-I targets cubilin suggesting that the CubAm complex is functional in our iPSCs-derived kidney organoids. Thus, kidney organoids provide a valuable system for modelling specific aspects of INS, including the impact of protein overload on tubular cells and the CubAm-mediated endocytosis of ApoA-I, which is thought to be impaired in these conditions., CLC performed this work within the basis of her thesis at the Department de Medicina of Universitat Autònoma de Barcelona. CJC performed a short stay in the Institute of Experimental Medicine and Systems Biology and Department of Medicine 2, RWTH Aachen University Hospital (Aachen, Germany) thanks to a travel grant of the Senefro Foundation of the Spanish Society of Nephrology (2023 call). This research was funded by Fundació la Marató de TV3, grant number 202017-10 and a grant from Instituto de Salud Carlos III (PI24/01573). The authors are recipients of other research grants from Instituto de Salud Carlos III (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD24/0004/0031). The Nephrology and Transplantation, the Renal Physiopathology and the Clinical Biochemistry, drug delivery and therapy research groups are recognized as a consolidated group by the Catalan Management Agency for University and Research Grants (2021 SGR 00883, 2021 SGR 01600 and 021 SGR 01173, respectively).
Scientia. Dipòsit d'Informació Digital del Departament de Salut
Publicación Artículo científico (JournalArticle)

Fibrillary glomerulonephritis: clinicopathological characteristics and treatment in a spanish tertiary center, Glomerulonefritis fibrilar: características clínico-patológicas y tratamiento en un centro terciario Español

  • Tatis Sáenz, Efraín Antonio
  • Gabaldon, Maria Alejandra
  • León-Román, Juan
  • Ramos Terrades, Natalia
  • Agraz Pamplona, Irene
  • López-Martínez, Marina
  • Núñez Delgado, Sara
  • TOAPANTA, NÉSTOR
  • Bermejo García, Sheila
  • Bestard, Oriol
  • Soler, María José
Fibrillary glomerulonephritis; Rituximab, Glomerulonefritis fibrilar; Rituximab, Glomerulonefritis fibril·lar; Rituximab, Introduction: Fibrillary glomerulonephritis (FGN) has a poor prognosis and lacks standardized treatment. In this study, we describe clinicopathological characteristics, clinical course, and management of patients with FGN at our center. Materials and methods: A retrospective cohort study of 13 patients diagnosed with FGN by positive DNAJB9 at kidney biopsy between 2019 and 2024. Demographic data, comorbidities, laboratory values, histopathological findings, and treatments were collected, Complete remission was defined as proteinuria <500 mg/g with normal renal function; partial remission as >50% reduction in proteinuria to <2000 mg/g with stable renal function; and no remission as absence of improvement, progression to end-stage kidney disease (ESKD), or death. Results: The mean age was 61.4 years, 69,2% male, median proteinuria of 2318 mg/g (38% nephrotic range) and serum creatinine 1.64 mg/dL, Histopathological findings: 29% global glomerulosclerosis. The most frequent pattern was membranoproliferative (61.6%), followed by mesangial (30.8%) and membranous in 1 patient (7.7%), Hypoalbuminemia (<3 g/dL) was associated with worse prognosis (HR 6.52, p = 0.04); proteinuria >3500 mg/g and creatinine showed non-significant trends. Immunosuppression was given in 84.6% of patients: rituximab (RTX) (61.5%), RTX + mycophenolate (7.7%), sequential RTX followed by ocrelizumab and obinutuzumab (7.7%), and corticosteroids alone (7.7%). Partial remission was achieved in 30.8%, all within the exclusive RTX group, A total of 38.4% progressed to ESKD or death. Conclusions: In our study, FGN showed poor prognosis and partial response to rituximab. FGN with hypoalbuminemia had worse outcomes. Prospective studies and larger cohorts are needed to validate these findings and optimize its management., Introducción La glomerulonefritis fibrilar (GNF) tiene un mal pronóstico y carece de tratamiento estandarizado. Materiales y métodos En este estudio analizamos las características clínicas y patológicas, evolución y manejo de 13 pacientes diagnosticados con GNF mediante biopsia renal positiva para DNAJB9 entre 2019 y 2024 en nuestro centro. Se recogieron datos demográficos, comorbilidades, valores de laboratorio, hallazgos histopatológicos y tratamientos. Se definió remisión completa como proteinuria <500 mg/g con función renal normal; remisión parcial como reducción >50% de proteinuria a <2000 mg/g con función renal estable; y sin remisión como ausencia de mejora, progresión a enfermedad renal crónica (ERC) estadio 5 o muerte. Resultados La media de edad fue 61,4 años, 69,2% hombres, con una proteinuria mediana de 2318 mg/g (38% en rango nefrótico) y creatinina sérica mediana de 1,64 mg/dL. Resultados de biopsia renal: el 29% de los glomérulos estaba esclerosado. El patrón histológico más frecuente fue el membranoproliferativo (61,6%), seguido del mesangial (30,8%) y membranosa (7,7%). La hipoalbuminemia (<3 g/dL) se asoció a peor pronóstico (HR 6,52, p = 0,04). La proteinuria >3500 mg/g y creatinina mostraron tendencias no significativas. El 84,6% recibió inmunosupresión: rituximab (RTX) (61,5%), RTX + micofenolato (7,7%), RTX seguido de ocrelizumab y obinutuzumab (7,7%), y corticoides en monoterapia (7,7%). Se consiguió remisión parcial en 30,8%, todos tratados con RTX en monoterapia. Un 38,4% progresó a ERC estadio 5 o falleció. Conclusión La GNF mostró mal pronóstico y respuesta parcial a RTX. La GNF con hipoalbuminemia presentó peor pronóstico. Se necesitan estudios prospectivos con mayores cohortes para confirmar estos hallazgos y optimizar su manejo., This study was funded by a research grant from Boehringer Ingelheim. JLR has a Río Hortega scholarship from the Carlos III Health Institute (CM23/00213). The authors are also beneficiaries of other research grants from the Carlos III Health Institute (PI21/01292, AC22/00029, INT23/00078, PI24/01510). The Nephrology and Transplantation group is part of the RICORS2040 network (RD21/0005/31 and RD24/0004/0031) and is recognized as a consolidated group by the Agency for University and Research Aid Management of Catalonia (2021 SGR 00883).